C-Brace Prospective Registry
Launched by OTTO BOCK HEALTHCARE PRODUCTS GMBH · Nov 17, 2020
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
The C-Brace Prospective Registry is a clinical trial designed to collect information on the safety and effectiveness of the C-Brace System, which helps people with lower limb weakness or paresis walk more easily. The trial is currently looking for participants of all ages who have successfully been tested for the C-Brace and are ready for fitting. To take part, individuals must be able to communicate and follow instructions during the study, and they need to agree to provide informed consent, which means they understand what the study involves.
If you or a loved one are interested in participating, you should know that the trial is open to anyone who meets the criteria, but those who live too far away to attend the required appointments or have not been fitted for a C-Brace will not be eligible. Participants can expect to share their experiences and feedback on how the C-Brace helps them during their daily activities. This information will help researchers understand how well the C-Brace works and ensure it is safe for users.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient has been evaluated and successfully tested with the Trial Tool, and has been casted for a C-Brace.
- • Patient is able to communicate, provide feedback, understand and follow instructions during the course of the registry.
- • Patient is willing to provide informed consent.
- Exclusion Criteria:
- • Patient is geographically inaccessible to comply and participate in the registry.
- • Patient has not been casted for a C-Brace fitting.
About Otto Bock Healthcare Products Gmbh
Otto Bock Healthcare Products GmbH is a leading global provider of innovative medical solutions, specializing in the development and manufacturing of advanced prosthetics, orthotics, and rehabilitation products. With a commitment to enhancing the quality of life for individuals with mobility challenges, the company leverages cutting-edge technology and extensive clinical research to deliver high-performance healthcare products. Otto Bock is dedicated to advancing patient care through rigorous clinical trials and collaborations with healthcare professionals, ensuring that their offerings meet the highest standards of safety, efficacy, and user satisfaction.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Antonio, Texas, United States
Houston, Texas, United States
Koblenz, Rhineland Palatinate, Germany
Exton, Pennsylvania, United States
San Diego, California, United States
Sarasota, Florida, United States
Chicago, Illinois, United States
Linthicum, Maryland, United States
Silver Spring, Maryland, United States
Rochester, Minnesota, United States
Mount Laurel, New Jersey, United States
Albuquerque, New Mexico, United States
Manhattan, New York, United States
New York, New York, United States
Jacksonville, North Carolina, United States
Pinehurst, North Carolina, United States
Wilmington, North Carolina, United States
Austintown, Ohio, United States
Philadelphia, Pennsylvania, United States
Kingsport, Tennessee, United States
Murfreesboro, Tennessee, United States
Conroe, Texas, United States
Fort Worth, Texas, United States
Houston, Texas, United States
Richmond, Virginia, United States
Roanoke, Virginia, United States
Everett, Washington, United States
Spokane, Washington, United States
Clayton, Victoria, Australia
Traunstein, Bavaria, Germany
Göttingen, Deutschland, Germany
Hanover, Lower Saxony, Germany
Palm Harbor, Florida, United States
Tampa, Florida, United States
Buford, Georgia, United States
Evansville, Indiana, United States
Fort Wayne, Indiana, United States
Danville, Kentucky, United States
Lexington, Kentucky, United States
Saint Louis, Missouri, United States
Mount Laurel, New Jersey, United States
Toms River, New Jersey, United States
Brooklyn, New York, United States
Akron, Ohio, United States
Exton, Pennsylvania, United States
Wakefield, Rhode Island, United States
Houston, Texas, United States
Saint George, Utah, United States
Renton, Washington, United States
San Diego, California, United States
Fairview Heights, Illinois, United States
Merrillville, Indiana, United States
Beverly, Massachusetts, United States
Clinton Township, Michigan, United States
Farmington Hills, Michigan, United States
Madison Heights, Michigan, United States
Fair Lawn, New Jersey, United States
Lenoir, North Carolina, United States
Pittsburgh, Pennsylvania, United States
Wyomissing, Pennsylvania, United States
Dallas, Texas, United States
Harrison, Arkansas, United States
Rogers, Arkansas, United States
Conyers, Georgia, United States
Frederick, Maryland, United States
Flint, Michigan, United States
Lansing, Michigan, United States
Lapeer, Michigan, United States
Livonia, Michigan, United States
Omaha, Nebraska, United States
Alburquerque, New Mexico, United States
Pittsburg, Pennsylvania, United States
Wyomissing, Pennsylvania, United States
York, Pennsylvania, United States
Spartanburg, South Carolina, United States
Austin, Texas, United States
Ferndale, Washington, United States
Richland, Washington, United States
Green Bay, Wisconsin, United States
Kobe, Hyogo, Japan
Patients applied
Trial Officials
Frank Braatz, Prof.
Principal Investigator
Private University of Applied Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials